Comparison · NCT02899299-sae
Nivolumab 3mg/kg Plus Ipilimumab 1mg/kg vs Pemetrexed Plus Cisplatin or Carboplatin: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Nivolumab 3mg/kg Plus Ipilimumab 1mg/kg vs Pemetrexed Plus Cisplatin or Carboplatin: serious adverse events. Trial comparisons, record NCT02899299-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02899299-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.627 | 0.571 | 0.679 | wilson | |
| Risk in group 2 | 0.373 | 0.319 | 0.431 | wilson | |
| Risk difference, group 1 minus group 2 | 0.253 | 0.173 | 0.329 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.68 | 1.41 | 2 | log | |
| Odds ratio, group 1 over group 2 | 2.82 | 2.02 | 3.94 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Nivolumab 3mg/kg Plus Ipilimumab 1mg/kg than on Pemetrexed Plus Cisplatin or Carboplatin | 3.95 | 3.04 | 5.78 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Nivolumab 3mg/kg Plus Ipilimumab 1mg/kg | Nivolumab 3 mg/kg IV Q2W + Ipilimumab 1 mg/kg IV Q6W | 188 | 300 | EG000 |
| Group 2 | Pemetrexed Plus Cisplatin or Carboplatin | Pemetrexed 500 mg/m\^2 + Cisplatin 75 mg/m\^2 or Carboplatin 5 AUC up to 6 cycles | 106 | 284 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
Participants were assessed for all-cause mortality from their first dose to their study completion (up to approximately 76 months.) SAEs and Other AEs were assessed from first dose to 100 days post the last dose of study therapy (up to approximately 29 months).
Source ClinicalTrials.gov
Trial
- Title
- Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients
- NCT number
- NCT02899299
- Phases
- PHASE3
- Conditions
- Mesothelioma
- Interventions
- Nivolumab, Ipilimumab, Pemetrexed, Cisplatin, Carboplatin
- Lead sponsor
- Bristol-Myers Squibb
- Results first posted
- 2021-04-14
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02899299?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02899299-sae